Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.
With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.
Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.
Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.
Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.
For more information, visit www.bauschhealth.com.
Bausch Health (BHC) reported strong financial results for Q4 and full-year 2024, marking its seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA. Fourth quarter revenues reached $2.56 billion, up 6% on a reported basis and 9% organically, while full-year revenues hit $9.63 billion, increasing 10% on a reported basis and 8% organically.
The company achieved Q4 GAAP Net Income of $93 million, though recorded a full-year net loss of $46 million. Consolidated Adjusted EBITDA grew 8% to $935 million in Q4 and 10% to $3.31 billion for the full year. All business segments showed growth, with particularly strong performance from Solta Medical (34% growth) and Bausch + Lomb (9% growth) in Q4.
Bausch Health Companies (NYSE/TSX: BHC) has announced its participation in the 2025 J.P. Morgan Global Leveraged Finance Conference in Miami Beach, Florida. The event is scheduled for Monday, February 24, 2025, at 8:45 a.m. EST.
The company will provide a live audio webcast of the event, which will be accessible through the Investor Relations section of Bausch Health's website. Interested parties can access the webcast at http://ir.bauschhealth.com/events-and-presentations. A replay of the event will be made available on the same investor relations website after the conference.
Bausch Health (NYSE/TSX: BHC) and its GI business, Salix Pharmaceuticals, have announced their 2025 Salix Gastrointestinal Health Scholars Program. The initiative will provide ten scholarships of up to $10,000 each to students living with GI diseases who are pursuing higher education.
This marks the sixth consecutive year of the program, which supports students attending two- or four-year colleges, universities, or advanced vocational/technical schools for the 2025-2026 academic year. The scholarships are available in three categories: Undergraduate Scholar Awards, Graduate Scholar Awards, and Working and/or Single Parents Scholar Awards.
Applicants must complete an online application, submit reference letters, and write an essay about their GI condition's impact on their life and their healthcare provider's role. The application period closes on May 5, 2025, with winners to be announced in summer 2025.
Bausch Health (NYSE/TSX: BHC) has provided an update regarding the potential sale of its Bausch + Lomb subsidiary, which was initially disclosed in December 2024. During the second half of 2024, while exploring liability management alternatives, Bausch + Lomb received an acquisition offer from a private equity firm. However, both companies' boards determined the offer didn't reflect Bausch + Lomb's long-term value and decided not to proceed with the sale.
Bausch Health will maintain its 88% ownership stake in Bausch + Lomb and continue working on liability management alternatives, including new debt financing. The company highlighted strong business performance in 2024, having raised its full-year guidance for revenue, adjusted EBITDA, and adjusted operating cash flow in October 2024. Fourth quarter and full-year 2024 earnings, along with 2025 guidance, will be reported on February 19, 2025.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has scheduled the release of its fourth quarter and full year 2024 financial results for Wednesday, February 19, 2025, after market close. The company will host a conference call and live webcast at 5:00 p.m. U.S. EST on the same day to discuss the results and provide a business update.
Interested parties can access all materials through the Investor Relations section of Bausch Health's website. A replay of the conference call will be made available on the investor relations website. To participate in the live Q&A session, participants must register in advance through the provided link.
Bausch Health (NYSE/TSX: BHC) announced that XIFAXAN® (rifaximin) 550 mg tablets has been selected by the Centers for Medicare and Medicaid Services (CMS) for the second round of price negotiations under the Inflation Reduction Act. The negotiated pricing will take effect in 2027.
The company plans to engage with CMS to demonstrate XIFAXAN's healthcare system value, highlighting recommendations from The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), which gave XIFAXAN® their highest recommendation (Grade I, A,1) in practice guidelines.
Bausch Health Companies (NYSE/TSX: BHC) has confirmed it is exploring potential sale options for its subsidiary Bausch + Lomb (NYSE/TSX: BLCO) as one of several alternatives to complete their separation. The statement was issued in response to a request from the Canadian Investment Regulatory Organization (CIRO) due to stock volatility concerns related to market rumors.
The company emphasized that while the Board of Directors has authorized management to explore a potential sale, no decision has been made to proceed with any particular transaction, and there is no guarantee that the process will result in a deal. The company stated it will not provide additional details until further disclosure becomes appropriate or necessary.
Bausch Health (NYSE/TSX:BHC) and its GI business, Salix Pharmaceuticals, along with major health organizations, are commemorating the second annual Opioid-Induced Constipation (OIC) Awareness Day on December 5, 2024. The initiative aims to raise awareness about OIC, a common side effect of opioid treatment.
According to statistics, approximately 21% of U.S. adults experienced chronic pain in 2021, with 22% of chronic pain patients receiving opioid prescriptions in 2019. To support the cause, Salix has updated the OICAwarenessDay.com website with resources for healthcare providers, patients, and caregivers. The campaign includes partnerships with influencers, a content program with Chronicon, and social media engagement using hashtags #OICAwarenessDay and #vOICesOfOIC.
Bausch Health (NYSE/TSX:BHC) has appointed Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. Dr. Sadeh brings over 20 years of experience in clinical research and drug development, most recently at Bristol-Meyers Squibb where he served as Senior Vice President and Global Programs Head. His track record includes multiple drug approvals in dermatology and gastroenterology. Dr. Sadeh holds a master's degree from Harvard Medical School and a medical degree from Mount Sinai School of Medicine, with previous experience at Sanofi, Astra-Zeneca, and Schering-Plough.
Bausch Health and Salix Pharmaceuticals announced the presentation of their RED-C Phase 3 clinical trial program at AASLD. The study evaluates a next-generation soluble solid dispersion (SSD) immediate-release rifaximin product designed to delay the onset of first overt hepatic encephalopathy (OHE) hospitalization in cirrhosis patients. The program consists of two global Phase 3 trials involving over 1,000 patients across 398 study sites in 17 countries. Patient enrollment is complete, with efficacy and safety results pending. The therapeutic aims to enhance gastrointestinal luminal solubility while limiting systemic exposure, addressing an unmet medical need as there are currently no approved medications for primary prophylaxis of OHE in cirrhosis.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
What are the primary areas of focus for Bausch Health?
How many employees does Bausch Health have?
In how many countries does Bausch Health operate?
What is Bausch Health's largest revenue-generating segment?
What recent product development has Bausch Health achieved?
What financial performance did Bausch Health report for Q1 2024?
How is Bausch Health protecting its intellectual property?
Where can I find more information about Bausch Health?
What recent public drug plan listings has Bausch Health achieved in Canada?
Who is the brand ambassador for the XIFAXAN® awareness campaign?
